CN1476872A - Medicine composition for curing diabetes - Google Patents
Medicine composition for curing diabetes Download PDFInfo
- Publication number
- CN1476872A CN1476872A CNA021393850A CN02139385A CN1476872A CN 1476872 A CN1476872 A CN 1476872A CN A021393850 A CNA021393850 A CN A021393850A CN 02139385 A CN02139385 A CN 02139385A CN 1476872 A CN1476872 A CN 1476872A
- Authority
- CN
- China
- Prior art keywords
- insulin
- diabetes
- pharmaceutical composition
- attapulgite
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The medicine composition for curing diabetes is formed from high-purity ultrafine attapulgite, insuline and palatability-regulating agent. It uses the attapulgite as adsorbing agent and slowly-releasing agent to adsorb the insuline for curing diabetes so as to provide a new dosage form instead of injection.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of diabetes.
Background technology
Diabetes are the not enough a kind of chronic metabolism disorder diseases that cause of relative secretory volume owing to insulin.Clinical manifestation is common eats more, drink more, polyuria and " three-many-one-little " symptom of losing weight, also may be with symptoms such as visual disorders, and each age all can fall ill.Acute and the chronic complication because diabetes can occur together, thereby be one of sickness rate and main causes of death.In many crowds all over the world, the prevalence of diabetes increases day by day, also is tangible ascendant trend in China.
Insulin is as the specific medicament of treatment diabetes, and traditional administering mode is subcutaneous injection or intravenous drip.Such application method is to cause handicapped and painful one of the main reasons to the insulin-dependent diabetics, and just they must remove insulin injection on time.Because insulin is orally give directly, begun development abroad and allowed insulin and the bonded oral tablet of high-molecular gel, finish the translocation of insulin by high-molecular gel, insulin after oral enters in the human body by the human consumption organ, the insulin tablet of developing as Russian physician and chemist " blue plain sheet ".
Attapulgite is the fibrous magnesia silicate of water-bearing layer chain, and only a few countries or such mineral deposit of regional output in the world are rare in the world nonmetal mineral resources at present.Have good physical property and unique element, architectural feature, be characterized by good colloidal property, absorption property and catalytic performance.
Abroad, U.S. particularly several thousand kinds of purposes of various fields such as has just developed from the oil drilling slurry to the solar energy heat-storage, though China has this mineral products advantage, but less to this mineral composition, structure and physical and chemical performance research, only develop several prods such as mud, adsorbent.Thereby, on the basis that composition, the performance of this resource are further studied, are familiar with, further develop application widely, develop high-purity micron, submicron-grade superfine powder body material, application to the ecological agriculture and life and health field has crucial meaning.
Because the high pure and ultra-fine attapulgite has that specific surface area is big, adsorptivity is strong, load is good, proportion is little, soda acid is moderate, pelletize uniformity, the characteristics such as depositing not classification of loosing.Therefore, the high pure and ultra-fine attapulgite can be used as the carrier of medicinal tool sustained release performance, and improves the performance and the route of administration of medicine.
Domestic still do not have this type of medicine, and the roughly the same medicine of Russia sieve phase invention " blue plain sheet " is only arranged in the world, and the mode of taking is similar to the present invention, but except that insulin, the composition of other and combination of the present invention, and principle all has essential difference, has been used for clinical at present.
Summary of the invention
The objective of the invention is for a kind of pharmaceutical composition for the treatment of diabetes is provided.Said composition is made the insulin of adsorbent and slow releasing agent adsorbing therapy diabetes with the high pure and ultra-fine attapulgite, thereby provides misery that a kind of new dosage form exempts injection and inconvenient for the insulin-dependent diabetics.Purpose of the present invention can realize by following measure:
A kind of pharmaceutical composition for the treatment of diabetes, make by known preparation process by following raw materials in percentage by weight:
Agreeable to the taste dose of 0-10% of high pure and ultra-fine attapulgite 40-80% insulin 20-40%.
Above-mentioned composition is to be made by following raw materials in percentage by weight:
Agreeable to the taste dose of 6-8% of high pure and ultra-fine attapulgite 55-64% Insulin 3 0-45%.
At least a in the above-mentioned agreeable to the taste dose of natural agreeable to the taste material that is selected from adhesion-molded effect sugar-free.
The dosage form of above-mentioned pharmaceutical composition is tablet, capsule, electuary.
The present invention has following advantage compared to existing technology:
Utilize in the medicine of the present invention to have specific surface area is big, adsorptivity is strong, load is good, proportion is little high pure and ultra-fine attapulgite adsorbent and carrier, thereby a kind of novel form of insulin is provided as the insulin of treatment diabetes; Because the effect that the oral agents of being made by the high pure and ultra-fine attapulgite can be resisted gastric acid, enter intestinal after, slowly discharge the insulin of its absorption, and be absorbed by the body.
Concrete embodiment
The present invention also will be described in further detail in conjunction with the embodiments:
Embodiment one:
A kind of pharmaceutical composition for the treatment of diabetes, make by following raw materials in percentage by weight: high-purity (97%) d=3 micron attapulgite 45%, insulin 49%, magnesium stearate 6%, make tablet by the preparation technology of known Tabules.
Embodiment two:
A kind of pharmaceutical composition for the treatment of diabetes, make by following raw materials in percentage by weight: high-purity (97%) d=3mm attapulgite 68%, insulin 26%, starch 6%, make electuary by known electuary technology.
Embodiment three:
A kind of pharmaceutical composition for the treatment of diabetes, make by following raw materials in percentage by weight: high-purity (90%) d=3 micron attapulgite 55%, Insulin 3 6%, capsule carrier 9%, make capsule by known capsule agent formulation technology.
Embodiment four:
A kind of pharmaceutical composition for the treatment of diabetes, make by following raw materials in percentage by weight: high-purity (97%) d=3mm attapulgite 40%, insulin 52%, starch 8%, make tablet by known tablet technology.
Embodiment five:
A kind of pharmaceutical composition for the treatment of diabetes, make by following raw materials in percentage by weight: high-purity (97%) d=3mm attapulgite 63%, Insulin 3 0%, starch 7%, make tablet by known tablet technology.
Embodiment six:
A kind of pharmaceutical composition for the treatment of diabetes, make by following raw materials in percentage by weight: high-purity (97%) d=3mm attapulgite 50%, insulin 40%, starch 10%, make tablet by known tablet technology.
Embodiment seven:
A kind of pharmaceutical composition for the treatment of diabetes, make by following raw materials in percentage by weight: high-purity (97%) d=3mm attapulgite 80%, insulin 20%, make tablet by known tablet technology.
Embodiment eight:
A kind of pharmaceutical composition for the treatment of diabetes, make by following raw materials in percentage by weight: high-purity (97%) d=3mm attapulgite 75%, insulin 20%, starch 5%, make tablet by known tablet technology.
Claims (4)
1, a kind of pharmaceutical composition for the treatment of diabetes, make by known preparation process by following raw materials in percentage by weight:
Agreeable to the taste dose of 0-10% of high pure and ultra-fine attapulgite 40-80% insulin 20-55%.
2, the pharmaceutical composition of treatment diabetes as claimed in claim 1 is characterized in that said composition is to be made by following raw materials in percentage by weight:
Agreeable to the taste dose of 6-8% of high pure and ultra-fine attapulgite 55-64% Insulin 3 0-45%.
3, the pharmaceutical composition of treatment diabetes as claimed in claim 1 is characterized in that described agreeable to the taste dose is selected from least a in the agreeable to the taste material of the sugar-free natural with adhesion-molded effect.
4, the pharmaceutical composition of treatment diabetes as claimed in claim 1, the agent preferred type that it is characterized in that described pharmaceutical composition is tablet, capsule, electuary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021393850A CN1476872A (en) | 2002-08-20 | 2002-08-20 | Medicine composition for curing diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021393850A CN1476872A (en) | 2002-08-20 | 2002-08-20 | Medicine composition for curing diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1476872A true CN1476872A (en) | 2004-02-25 |
Family
ID=34147423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021393850A Pending CN1476872A (en) | 2002-08-20 | 2002-08-20 | Medicine composition for curing diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1476872A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751150A (en) * | 2013-12-23 | 2014-04-30 | 杨立新 | Method for preparing insulin sustained-release capsules from attapulgite |
-
2002
- 2002-08-20 CN CNA021393850A patent/CN1476872A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751150A (en) * | 2013-12-23 | 2014-04-30 | 杨立新 | Method for preparing insulin sustained-release capsules from attapulgite |
| CN103751150B (en) * | 2013-12-23 | 2016-01-20 | 杨立新 | A kind of method applied attapulgite and prepare insulin slow release capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1136874C (en) | Composite medicine for treating hyperlipemia | |
| CN1476872A (en) | Medicine composition for curing diabetes | |
| CN1628768A (en) | Medicine for treating gout affection and its symptoms | |
| CN1733031A (en) | Brain caring oral liquid and its preparation process | |
| CN1267103C (en) | Applicaton of montmorillonite inpreparing medicine | |
| CN1186017C (en) | Process for preparing medicine to prevent and cure diabetes, hyperlipomia and obesity | |
| CN1759871A (en) | Hemostasis capsule and preparation technique | |
| CN1177603C (en) | Gingko leaf slow-releasing table and preparation process thereof | |
| WO2021068459A1 (en) | Suspension containing low methoxylation pectin and montmorillonite for treating acute diarrhea | |
| CN103070842A (en) | Preparation method of miglitol sustained release tablet | |
| CN1255132C (en) | Nasosinusitis treating medicine and its preparing process | |
| CN1277553C (en) | Redy preparation Chinese medicine for treating kinetic fatigue and chronic fatigue syndrome | |
| CN101125147A (en) | Glucosamine calcium medicine preparation, preparation method and application thereof | |
| CN1679557A (en) | Compound chlorzoxazone tablets | |
| CN1872110A (en) | Application of preparation of notoginseng extractive in resistant medication anti aspirin | |
| CN102233049A (en) | Chinese medicine for curing diabetes | |
| CN1583173A (en) | Serial hypertension treating medicine and new medicine developing, applying and producing and packing technology | |
| CN1306857A (en) | Medicine for strengthening physique and strengthening immunity | |
| CN1438011A (en) | Compound Huangyangning (Chinese littleleaf box) small pills | |
| CN1562172A (en) | Capsule of Chinese traditional medicine for treating cough and asthma, and preparation method | |
| CN1742754A (en) | Zhibituo dispersion tablet and preparing method | |
| CN1385204A (en) | Antianaphylactic Chinese medicine preparation | |
| CN1686322A (en) | Blood fat reducing granules containing seed of pepper weed or flixweed tansymustard | |
| CN101152297A (en) | Traditional Chinese medicine for treating postoperative paralytic ileus | |
| CN101167956A (en) | Ointment for treating ulcer and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |